Express News | Bradley L. Radoff and Michael Torok: Collectively Own About 3% of Outstanding Shares of Atea Pharmaceuticals

BreakingsDec 19 06:29

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

BusinesswireDec 19 06:05

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

GlobeNewswireDec 16 18:00

Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.2

Futu NewsDec 6 01:31 · Ratings

Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges

TipRanksDec 6 01:18 · Ratings

Atea Pharmaceuticals Reports 98% Sustained Virologic Response in Phase 2 Study of Hepatitis C Treatment, Plans Phase 3 Program for 2025

BarchartDec 5 06:16